SCHEMBL3005397

SCHEMBL3005397

COc1cc(OC)cc(-c2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4Cl)CC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
HSD17B10 Q99714 3/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
CTSS P25774 4/20 0.47
SMN1; SMN2 Q16637 5/20 0.45
RAB9A P51151 3/20 0.45
ALDH1A1 P00352 6/20 0.44
LMNA P02545 6/20 0.44
MAPK1 P28482 5/20 0.44
TP53 P04637 2/20 0.44
HTT P42858 1/20 0.44
AR P10275 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPC1 O15118 2/20 0.43
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HPGD P15428 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013197 0.93 RAB9A (0.54) MAPTHSD17B10USP2RECQLCTSS
SCHEMBL3019881 0.92 MAPT (0.63) MAPTHSD17B10USP2RECQLCTSS
SCHEMBL3015484 0.91 MAPT (0.51) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3015770 0.91 RAB9A (0.46) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3009745 0.90 ALDH1A1 (0.52) MAPTHSD17B10USP2RECQLCTSS
SCHEMBL3016485 0.89 RAB9A (0.45) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL3008195 0.89 CTSS (0.51) MAPTHSD17B10USP2RECQLCTSS
SCHEMBL3011275 0.89 CTSS (0.51) MAPTHSD17B10USP2RECQLCTSS
SCHEMBL3018230 0.88 MAPT (0.51) MAPTHSD17B10USP2RECQLSMN1; SMN2
SCHEMBL2998094 0.88 MAPT (0.50) MAPTHSD17B10USP2RECQLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885HSD17B10 2553/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.